10-Q: AngioDynamics Reports Mixed Results in Q2 2025, Driven by Divestitures and Restructuring

AngioDynamics' Q2 2025 results show a decrease in revenue due to divestitures, but an increase in gross profit margin and a reduction in net loss.

Summary

• AngioDynamics reported a net loss of $10.7 million, or $0.26 per share, on net sales of $72.8 million for the three months ended November 30, 2024.
• This compares to a net loss of $29.0 million, or $0.72 per share, on net sales of $79.1 million for the same period last year.
• For the six months ended November 30, 2024, the company reported a net loss of $23.5 million, or $0.58 per share, on net sales of $140.3 million.
• This is compared to a net income of $16.8 million, or $0.42 per share, on net sales of $157.8 million for the same period last year.
• The decrease in revenue is partially due to the sale of the PICCs, Midline, dialysis and BioSentry businesses, along with the discontinuation of the RadioFrequency Ablation and Syntrax product lines, which impacted sales by $12.4 million and $24.3 million for the three and six month periods, respectively.
• The Med Tech segment saw revenue growth of 24.4% in the second quarter of fiscal year 2025, while the Med Device segment declined by 23.1%.
• Gross profit margin increased to 54.8% for the quarter and 54.6% for the six months, driven by sales volume, price and product mix.
• The company repurchased 171,706 shares of common stock at an aggregate cost of $1.1 million during the second quarter of fiscal year 2025.
• AngioDynamics is undergoing a restructuring of its manufacturing footprint, which is expected to be completed in the third quarter of fiscal year 2026 and generate $15.0 million in annual cost savings in fiscal year 2027.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to decreased revenue and net losses, although there are some positive aspects such as improved gross profit margin and cost-saving restructuring efforts. The company is facing challenges but is taking steps to address them.

Positives

• Med Tech segment revenue showed strong growth of 24.4% in the second quarter of fiscal year 2025.
• Gross profit margin improved to 54.8% for the quarter and 54.6% for the six months ended November 30, 2024.
• Net loss decreased by $18.3 million to $10.7 million for the three months ended November 30, 2024.
• Cash used in operations decreased by $4.9 million to $15.8 million for the six months ended November 30, 2024.
• The company is implementing a restructuring plan that is expected to generate $15.0 million in annual cost savings by fiscal year 2027.

Negatives

• Net sales decreased by 7.9% to $72.8 million for the three months and 11.0% to $140.3 million for the six months ended November 30, 2024.
• The Med Device segment experienced a significant revenue decline of 23.1% in the second quarter of fiscal year 2025.
• The company reported a net loss of $10.7 million for the three months and $23.5 million for the six months ended November 30, 2024.
• The company is facing ongoing legal proceedings and has made a $7.0 million payment to settle litigation with Becton, Dickinson and Company.

Risks

• The company is exposed to market risk from changes in currency exchange rates, particularly with the Euro, British Pound and Canadian Dollar.
• The company is involved in various legal proceedings, including product liability claims, which could result in material losses.
• The company's restructuring plan may not achieve the expected cost savings or may encounter unforeseen challenges.
• The company's ability to obtain financing in the future could be impacted by market conditions.
• The company's sales and profitability growth depends on the introduction of new and innovative products, which may not be successful.

Future Outlook

The company expects its businesses to grow in both sales and profitability by expanding geographically, penetrating new markets, introducing new products and increasing its presence internationally. The modified manufacturing restructuring plan is expected to generate $15.0 million in annual cost savings in fiscal year 2027.

Management Comments

• Management continues to evaluate the company's liquidity position, communicate with and monitor the actions of customers and suppliers, and review near-term financial performance.
• Management believes that the current cash balance, together with cash generated from operations, will provide sufficient liquidity to meet anticipated needs for capital for at least the next 12 months.

Industry Context

The medical device industry is experiencing changing market dynamics, including value-based purchasing, consolidation of healthcare providers, and an aging population. AngioDynamics is adapting to these changes through strategic divestitures, restructuring, and a focus on innovative products. The company is also facing increased competition and regulatory scrutiny, which are common challenges in the industry.

Comparison to Industry Standards

• AngioDynamics' revenue decline of 7.9% for the quarter is worse than some of its peers in the medical device industry, which have shown modest growth or stability.
• Companies like Medtronic and Boston Scientific have reported more stable revenue figures, although they operate in different segments of the medical device market.
• The gross profit margin improvement to 54.8% is a positive sign, but it still lags behind some of the industry leaders who often have margins above 60%.
• The company's restructuring efforts are similar to actions taken by other medical device companies to improve efficiency and reduce costs, such as Johnson & Johnson's restructuring initiatives.
• The legal settlement with Becton, Dickinson and Company is a common occurrence in the medical device industry, where intellectual property disputes are frequent.

Legal Proceedings

• The company is defending approximately 50 product liability claims involving its port products.
• The company made a one-time lump sum payment of $7.0 million to Becton, Dickinson and Company to settle ongoing litigations, with additional payments due over time.

Stakeholder Impact

• Shareholders are impacted by the decreased revenue and net losses, but may benefit from the cost-saving restructuring efforts and share repurchase program.
• Employees are impacted by the manufacturing restructuring plan, which may result in job losses.
• Customers may be impacted by changes in product offerings and manufacturing processes.
• Suppliers may be impacted by changes in the company's supply chain.

Next Steps

• The company will continue to execute its manufacturing restructuring plan, which is expected to be completed in the third quarter of fiscal year 2026.
• The company will continue to monitor the market and its financial performance.
• The company will continue to develop and introduce new products.
• The company will continue to evaluate potential acquisitions of other businesses or technologies.

Key Dates

Keywords

AngioDynamics, Medical Devices, Financial Results, Restructuring, Divestiture, Med Tech, Med Device, Gross Profit, Net Loss, Share Repurchase, Legal Proceedings